+44 20 8123 2220
info@marketpublishers.com

Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

https://marketpublishers.com/r/R3D1DDCD9BAEN.html
Date: October 2017
Pages: 0
Price: US$ 3,600.00 (Single User License)
ID: R3D1DDCD9BAEN

Abstracts

Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

mRNA is a rather versatile therapeutic modality and offers a range of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

It is increasingly recognized that oncolytic viruses not only are able to directly lyse cancer cells, but they also „free“ tumor specific neoantigens, indirectly acting as a cancer vaccine. The so far modest efficacy of oncolytic viruses still can be improved when combined with immune checkpoint inhibitors. This lead to an increased partnering interest of the major immuno-oncology (I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens. Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo.

The original reports were published in January and June 2017, respectively:

> The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

+44 20 8123 2220
info@marketpublishers.com

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

4 PIPELINE ANALYSIS

5 PROFILES OF SELECTED MRNA & DELIVERY TECHNOLOGIES

+44 20 8123 2220
info@marketpublishers.com

6 TECHNOLOGY ANALYSIS

7 COMPANY PROFILES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

THE ONCOLYTIC VIRUS LANDSCAPE 2017: AN ANALYSIS OF PIPELINE, STAKEHOLDERS, DEALS, INDUSTRY TRENDS & OPPORTUNITIES

+44 20 8123 2220
info@marketpublishers.com

5 ANALYSIS OF ONCOLYTIC VIRUS PIPELINE

+44 20 8123 2220
info@marketpublishers.com

6 COMPANY PROFILES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

10 REFERENCES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

Product link: https://marketpublishers.com/r/R3D1DDCD9BAEN.html

Price: US$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/R3D1DDCD9BAEN.html